Abstract
Diffuse large B-cell lymphoma (DLBCL), the most common subtype of non-Hodgkin's lymphoma, is clinically heterogeneous: 40% of patients respond well to current therapy and have prolonged survival, whereas the remainder succumb to the disease. We proposed that this variability in natural history reflects unrecognized molecular heterogeneity in the tumours. Using DNA microarrays, we have conducted a systematic characterization of gene expression in B-cell malignancies. Here we show that there is diversity in gene expression among the tumours of DLBCL patients, apparently reflecting the variation in tumour proliferation rate, host response and differentiation state of the tumour. We identified two molecularly distinct forms of DLBCL which had gene expression patterns indicative of different stages of B-cell differentiation. One type expressed genes characteristic of germinal centre B cells (‘germinal centre B-like DLBCL’); the second type expressed genes normally induced during in vitro activation of peripheral blood B cells (‘activated B-like DLBCL’). Patients with germinal centre B-like DLBCL had a significantly better overall survival than those with activated B-like DLBCL. The molecular classification of tumours on the basis of gene expression can thus identify previously undetected and clinically significant subtypes of cancer.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Hodgkin, T. On some morbid appearances of the absorbant glands and spleen. Med.-Chir. Trans. 17, 68–114 (1832).
Sternberg, C. Über eine eigenartige unter dem Bilde der Pseudoleukamie verlaufende Tuberculose des lymphatischen Apparates. Heilk 19, 21–90 (1898).
Reed, D. M. On the pathological changes in Hodgkin's disease, with especial reference to its relation to tuberculosis. Johns Hopkins Hosp. Rep. 10, 133–196 (1902).
Rosenberg, S. A. Classification of lymphoid neoplasms. Blood 84, 1359–1360 (1994).
Harris, N. L. et al. A revised European–American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 84, 1361–1392 ( 1994).
The Non-Hodgkin's Lymphoma Classification Project : A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood 89, 3909–3918 (1997).
Vose, J. M. Current approaches to the management of non-Hodgkin's lymphoma. Semin. Oncol. 25, 483–491 (1998).
The International Non-Hodgkin's Lymphoma Prognostic Factors Project: A predictive model for aggressive non-Hodgkin's lymphoma. N. Engl. J. Med. 329, 987– 994 (1993).
Klein, U. et al. Somatic hypermutation in normal and transformed human B cells. Immunol. Rev. 162, 261–280 (1998).
Schena, M., Shalon, D., Davis, R. W. & Brown, P. O. Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science 270, 467–470 ( 1995).
Bubendorf, L. et al. Hormone therapy failure in human prostate cancer: analysis by complementary DNA and tissue microarrays. J. Natl Cancer Inst. 91, 1758–1764 ( 1999).
Wang, K. et al. Monitoring gene expression profile changes in ovarian carcinomas using cDNA microarray. Gene 229, 101– 108 (1999).
Golub, T. R. et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 286 , 531–537 (1999).
Khan, J. et al. Gene expression profiling of alveolar rhabdomyosarcoma with cDNA microarrays. Cancer Res. 58, 5009– 5013 (1998).
Perou, C. M. et al. Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proc. Natl Acad. Sci. USA 96, 9212–217 (1999).
DeRisi, J. et al. Use of a cDNA microarray to analyse gene expression patterns in human cancer. Nature Genet. 14, 457– 460 (1996).
Alon, U. et al. Broad patterns of gene expression revealed by clustering analysis of tumor and normal colon tissues probed by oligonucleotide arrays. Proc. Natl Acad. Sci. USA 96, 6745– 6750 (1999).
Alizadeh, A. et al. The Lymphochip: a specialized cDNA microarray for the genomic-scale analysis of gene expression in normal and malignant lymphocytes. Cold Spring Harbor Symp. Quant. Biol. (in the press).
Alizadeh, A., Eisen, M., Botstein, D., Brown, P. O. & Staudt, L. M. Probing lymphocyte biology by genomic-scale gene expression analysis. J. Clin. Immunol. 18, 373–379 (1998).
Eisen, M. B., Spellman, P. T., Brown, P. O. & Botstein, D. Cluster analysis and display of genome-wide expression patterns. Proc. Natl Acad. Sci. USA 95, 14863– 14868 (1998).
Grogan, T. M. et al. Independent prognostic significance of a nuclear proliferation antigen in diffuse large cell lymphomas as determined by the monoclonal antibody Ki-67. Blood 71, 1157–1160 (1988).
Staudt, L. M., Dent, A. L., Shaffer, A. L. & Yu, X. Regulation of lymphocyte cell fate decisions and lymphomagenesis by BCL-6. Int. J. Immunol. 18, 381–403 (1999).
Bahler, D. W. & Levy, R. Clonal evolution of a follicular lymphoma: evidence for antigen selection. Proc. Natl Acad. Sci. USA 89, 6770–6774 (1992).
Liu, Y. -J. & Banchereau, J. in Handbook of Experimental Immunology (eds Weir, D., Blackwell, C., Herzenberg, L. & Herzenberg, L.) 93.1–93.9 (Blackwell Scientific, Oxford, 1996).
Golay, J., Erba, E., Bernasconi, S., Peri, G. & Introna, M. The A-myb gene is preferentially expressed in tonsillar CD38+, CD39-, and sIgM- B lymphocytes and in Burkitt's lymphoma cell lines. J. Immunol. 153, 543–553 ( 1994).
Kuo, F. C. & Sklar, J. Augmented expression of a human gene for 8-oxoguanine DNA glycosylase (MutM) in B lymphocytes of the dark zone in lymph node germinal centers. J. Exp. Med. 186, 1547–1556 (1997).
Flenghi, L. et al. A specific monoclonal antibody (PG-B6) detects expression of the BCL-6 protein in germinal center B cells. Am. J. Pathol . 147, 405–411 ( 1995).
Pittaluga, S. et al. BCL-6 expression in reactive lymphoid tissue and in B-cell non-Hodgkin's lymphomas. J. Pathol. 179, 145–150 (1996).
Zani, V. J. et al. Molecular cloning of complex chromosomal translocation t(8;14;12)(q24. 1;q32. 3;q24. 1) in a Burkitt lymphoma cell line defines a new gene (BCL7A) with homology to caldesmon. Blood 87, 3124 –3134 (1996).
Fukuda, T. et al. Disruption of the Bcl6 gene results in an impaired germinal center formation. J. Exp. Med. 186, 439– 448 (1997).
Ye, B. H. et al. The BCL-6 proto-oncogene controls germinal-centre formation and Th2-type inflammation. Nature Genet. 16, 161–170 (1997).
Dent, A. L., Shaffer, A. L., Yu, X., Allman, D. & Staudt, L. M. Control of inflammation, cytokine expression, and germinal center formation by BCL-6. Science 276, 589–592 (1997).
Rabbitts, T. H. LMO T-cell translocation oncogenes typify genes activated by chromosomal translocations that alter transcription and developmental processes. Genes Dev. 12, 2651–2657 ( 1998).
Iida, S. et al. Deregulation of MUM1/IRF4 by chromosomal translocation in multiple myeloma. Nature Genet. 17, 226– 230 (1997).
Matsuyama, T. et al. Molecular cloning of LSIRF, a lymphoid-specific member of the interferon regulatory factor family that binds the interferon-stimulated response element (ISRE). Nucleic Acids Res. 23, 2127–2136 (1995).
Mittrucker, H. W. et al. Requirement for the transcription factor LSIRF/IRF4 for mature B and T lymphocyte function. Science 275, 540–543 (1997).
Tschopp, J., Irmler, M. & Thome, M. Inhibition of fas death signals by FLIPs. Curr. Opin. Immunol. 10, 552–558 ( 1998).
Djerbi, M. et al. The inhibitor of death receptor signaling, FLICE-inhibitory protein defines a new class of tumor progression factors. J. Exp. Med. 190, 1025–1031 ( 1999).
Medema, J. P., de Jong, J., van Hall, T., Melief, C. J. M. & Offringa, R. Immune escape of tumors in vivo by expression of cellular FLICE-inhibitory protein. J. Exp. Med. 190, 1033–1038 (1999).
Fisher, R. I. et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N. Engl. J. Med. 328, 1002–1006 ( 1993).
Jalkanen, S., Joensuu, H., Soderstrom, K. O. & Klemi, P. Lymphocyte homing and clinical behavior of non-Hodgkin's lymphoma. J. Clin. Invest. 87, 1835–1840 (1991).
Harada, S. et al. Molecular and immunological dissection of diffuse large B cell lymphoma: CD5-, and CD5- with CD10+ groups may constitute clinically relevant subtypes. Leukemia 13, 1441– 1447 (1999).
Kramer, M. H. et al. Clinical significance of bcl2 and p53 protein expression in diffuse large B-cell lymphoma: a population-based study. J. Clin. Oncol. 14, 2131–2138 ( 1996).
Preti, H. A. et al. Prognostic value of serum interleukin-6 in diffuse large-cell lymphoma. Ann. Int. Med. 127, 186– 194 (1997).
Gascoyne, R. D. et al. Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma. Blood 90, 244–251 ( 1997).
Kramer, M. H. et al. Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma. Blood 92, 3152–3162 (1998).
Klein, U., Rajewsky, K. & Kuppers, R. Human immunoglobulin (Ig)M+IgD+ peripheral blood B cells expressing the CD27 cell surface antigen carry somatically mutated variable region genes: CD27 as a general marker for somatically mutated (memory) B cells. J. Exp. Med. 188, 1679– 1689 (1998).
Tangye, S. G., Liu, Y. J., Aversa, G., Phillips, J. H. & de Vries, J. E. Identification of functional human splenic memory B cells by expression of CD148 and CD27. J. Exp. Med. 188, 1691–1703 (1998).
Allman, D. et al. BCL-6 expression during B-cell activation. Blood 87, 5257–5268 (1996).
Eisen, M. B. & Brown, P. O. DNA arrays for analysis of gene expression. Methods Enzymol. 303, 179– 205 (1999).
Acknowledgements
We acknowledge the support of the Cancer Genome Anatomy Project (CGAP), led by B. Strausberg and R. Klausner. We also thank R. Klausner for comments on the manuscript; C. Prange for providing CGAP cDNA clones; H. Messner for providing DLBCL cell lines; H. Mostowski for sorting lymphocyte subpopulations by FACS; Holy Cross Hospital, Silver Spring, Maryland, for providing human tonsils; J. DeRisi for helpful advice on microarray technology; and members of the Staudt, Brown and Botstein laboratories for helpful discussions. Research at Stanford was supported by grants from the National Cancer Institute to D.B., R.L. and P.O.B. and by the Howard Hughes Medical Institute. P.O.B. is an Associate Investigator of the Howard Hughes Medical Institute. A.A. was initially supported by the Howard Hughes Medical Institute Research Scholar Program while at the NIH and then by the Medical Scientist Training Program at Stanford University. M.B.E. was supported by a Computational Molecular Biology Postdoctoral Fellowship from the Alfred E. Sloan Foundation.
Author information
Authors and Affiliations
Corresponding author
Supplementary information
Rights and permissions
About this article
Cite this article
Alizadeh, A., Eisen, M., Davis, R. et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403, 503–511 (2000). https://doi.org/10.1038/35000501
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/35000501
This article is cited by
-
Interplay between proteasome inhibitors and NF-κB pathway in leukemia and lymphoma: a comprehensive review on challenges ahead of proteasome inhibitors
Cell Communication and Signaling (2024)
-
Machine learning analysis of gene expression reveals TP53 Mutant-like AML with wild type TP53 and poor prognosis
Blood Cancer Journal (2024)
-
Integrative analyses reveal outcome-associated and targetable molecular partnerships between TP53, BRD4, TNFRSF10B, and CDKN1A in diffuse large B-cell lymphoma
Annals of Hematology (2024)
-
A promising natural product in diffuse large B-cell lymphoma therapy by targeting PIM1
Annals of Hematology (2024)
-
Development and validation of a novel risk stratification model and a survival rate calculator for diffuse large B-cell lymphoma in the rituximab era: a multi-institutional cohort study
Annals of Hematology (2024)